Nutritional Strategies for Battling Obesity-Linked Liver Disease: the Role of Medical Nutritional Therapy in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management

Current Obesity Reports, Journal Year: 2025, Volume and Issue: 14(1)

Published: Jan. 11, 2025

This narrative review explores the role of Medical Nutritional Therapy (MNT) in managing Metabolic-Associated Steatotic Liver Disease (MASLD), previously known as nonalcoholic fatty liver disease. It aims to examine effectiveness specific nutritional strategies preventing and treating this obesity-linked Emerging evidence underscores benefits Mediterranean diet, low-carbohydrate diets, intermittent fasting reducing fat, improving insulin sensitivity, mitigating inflammation. Supplementing with vitamin E, omega-3 acids, silymarin can potentially reduce fibrosis promote health. MNT is a key intervention for MASLD management, emphasizing dietary patterns, caloric restriction, nutraceutical supplementation. Integrating these lifestyle modifications, including regular physical activity, offers comprehensive approach metabolic outcomes patients MASLD. Further research needed refine personalize therapeutic interventions.

Language: Английский

---

Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Nutrients, Journal Year: 2024, Volume and Issue: 17(1), P. 143 - 143

Published: Dec. 31, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major contributor to liver-related morbidity, cardiovascular disease, and metabolic complications. Lifestyle interventions, including diet exercise, are first line in treating MASLD. Dietary approaches such as the low-glycemic-index Mediterranean diet, ketogenic intermittent fasting, high fiber diets have demonstrated potential addressing dysfunction underlying this condition. The development progression of MASLD closely associated with taxonomic shifts gut microbial communities, relationship well-documented literature. Given importance primary treatment for MASLD, it important understand how microbiota their byproducts mediate favorable outcomes induced by healthy dietary patterns. Conversely, changes conferred unhealthy patterns Western may induce dysbiosis influence through promoting hepatic inflammation, up-regulating lipogenesis, dysregulating bile acid metabolism, increasing insulin resistance, causing oxidative damage hepatocytes. Although emerging evidence has identified links between microbiota, significant gaps remain understanding specific roles, metabolite pathways, host interactions, causal relationships. Therefore, review aims provide mechanistic insights into role microbiota-mediated processes analysis both contribution pathophysiology. By better elucidating interplay nutrients, processes, onset work identify new opportunities targeted interventions treat efficiently.

Language: Английский

---

Cluster analysis of diet and lifestyle factors associated with metabolic dysfunction-associated steatotic liver disease: findings from Korean Genome and Epidemiology Study

Endocrine, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

---

The relationship between smoking cessation history and significant liver fibrosis among the population with metabolic dysfunction-associated steatotic liver disease in the United States

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(4), P. e0320573 - e0320573

Published: April 1, 2025

Background Smoking was identified as a risk factor for the development of liver fibrosis in patients with metabolic dysfunction-associated steatotic disease (MASLD). However, association between smoking cessation history and remains unclear. This study intended to analyze significant adult MASLD participants United States. Methods utilized data from 2643 National Health Nutrition Examination Survey (NHANES). Significant detected based on transient elastography measurements. According questionnaire data, were categorized non-smokers, ex-smokers current smokers. A multivariate logistic regression analysis, adjusted weights, performed investigate relationship presence MASLD. Results total included this study. Compared had slightly elevated developing (OR: 1.07, 95% CI: 1.02–1.13). Specifically, positive correlation observed who quit < 20 years 1.01–1.15). Furthermore, started regularly at an age ≤ 1.09, 1.02–1.16) duration ≥ 10 before quitting 1.10, 1.02–1.18) also highly correlated increased likelihood fibrosis. Conclusions revealed that individuals have ceased exhibit when compared those never smoked. It is emphasized years, should be extremely vigilant regarding

Language: Английский

---

Potential Therapeutic Exploitation of G Protein-Coupled Receptor 120 (GPR120/FFAR4) Signaling in Obesity-Related Metabolic Disorders

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(6), P. 2501 - 2501

Published: March 11, 2025

The increasing prevalence of overweight and obesity not only in adults but also among children adolescents has become one the most alarming health problems worldwide. Metabolic disorders accompanying fat accumulation during pathological weight gain induce chronic low-grade inflammation, which, a vicious cycle, increases immune response through pro-inflammatory changes cytokine (adipokine) profile. Obesity decreases life expectancy, largely because obese individuals are at an increased risk many medical complications, often referred to as metabolic syndrome, which refers co-occurrence insulin resistance (IR), impaired glucose tolerance, type 2 diabetes (T2D), atherogenic dyslipidemia, hypertension, premature ischemic heart disease. Metabotropic G protein-coupled receptors (GPCRs) constitute numerous diverse group cell surface transmembrane eukaryotes. Among GPCRs, researchers focusing on connection receptor 120 (GPR120), known free fatty acid 4 (FFAR4), with signaling pathways regulating inflammatory sensitivity. This review presents current state knowledge concerning involvement GPR120 anti-inflammatory signaling. Since both inflammation adipose tissue key obesity, there is rationale for development novel, GPR120-based therapies individuals. main associated introducing this treatment into clinical practice discussed.

Language: Английский

---

High-Sensitivity C-Reactive Protein Levels in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Alcohol-Associated Liver Disease (MetALD), and Alcoholic Liver Disease (ALD) with Metabolic Dysfunction

Biomolecules, Journal Year: 2024, Volume and Issue: 14(11), P. 1468 - 1468

Published: Nov. 18, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a recently introduced term for (SLD). Although the inflammatory process central to pathogenesis of SLD, research investigating differences in systemic inflammation across various SLD subtypes as well sex limited. This population-based, cross-sectional study investigated association between and high-sensitivity C-reactive protein (hs-CRP) levels among Korean adults (N = 20,141; mean age: 50.8 ± 16.7 years). The participants were classified into five groups that included no MASLD, metabolic alcohol-associated (MetALD), alcoholic with dysfunction (ALD MD), other SLDs. median (Q1, Q3) value hs-CRP level was 0.54 mg/L (0.33, 1.04). Among men, compared group, MetALD, ALD MD associated 41.9% (95% confidence interval [CI]: 35.1-49.1%), 46.8% CI: 35.0-59.6%), 51.8% 30.0-77.2%) increases levels, respectively. stronger women, 81.5% 73.6-89.8%), 84.3% 58.1-114.8%), 98.2% 38.0-184.8%) In conclusion, our findings indicate varying profile subtypes, more pronounced women

Language: Английский

---

Diagnosis and Management of Metabolic Dysfunction- Associated Steatotic Liver Disease in South Asians- A Clinical Review

Obesity Pillars, Journal Year: 2024, Volume and Issue: 12, P. 100142 - 100142

Published: Oct. 11, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed as nonalcoholic fatty (NAFLD) is a hepatic manifestation of obesity and metabolic syndrome. It mainly caused by insulin resistance. With the increased risk visceral in South Asians, prevalence MASLD on rise. The morbidity associated with its complications, including hepatocellular carcinoma projected to increase this Asian population.

Language: Английский

---

Association of serum selenium with MASLD and liver fibrosis: A cross-sectional study

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(12), P. e0314780 - e0314780

Published: Dec. 31, 2024

The evolution of NAFLD, MAFLD, and MASLD underscores significant advancements nomenclatural shifts in the realm chronic liver disorders. This study primarily aimed to investigate possible link between serum selenium levels occurrence MASLD.

Language: Английский

---